Evidence map›Paper›PMID 37376170›Full record

ArticlePharmaceutics2023

Biocomposite for Prolonged Release of Water-Soluble Drugs.

Lyghia M A Meirelles, Raquel de Melo Barbosa, Renato Ferreira de Almeida Júnior, Paula Renata Lima Machado, Luana Perioli, César Viseras, Fernanda Nervo Raffin

Open access · goldAbstract read
In one paragraph

Article in Pharmaceutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 3 countries.

Lyghia M A MeirellesLaboratory of Drug Development, Department of Pharmacy, Federal University of Rio Grande do Norte, Natal 59012-570, Brazil.
Raquel de Melo BarbosaLaboratory of Drug Development, Department of Pharmacy, Federal University of Rio Grande do Norte, Natal 59012-570, Brazil.ORCID 0000-0003-3798-5512
Renato Ferreira de Almeida JúniorImmunology Laboratory, Pharmacy Faculty, Federal University of Rio Grande do Norte, Natal 59010-180, Brazil.
Paula Renata Lima MachadoImmunology Laboratory, Pharmacy Faculty, Federal University of Rio Grande do Norte, Natal 59010-180, Brazil.
Luana PerioliDepartment of Pharmaceutic Science, University of Perugia, 06123 Perugia, Italy.ORCID 0000-0003-3890-3283
César ViserasDepartment of Pharmacy and Pharmaceutical Technology, Faculty of Pharmacy, Campus de Cartuja s/n, University of Granada, 18071 Granada, Spain.ORCID 0000-0002-2219-3566
Fernanda Nervo RaffinLaboratory of Drug Development, Department of Pharmacy, Federal University of Rio Grande do Norte, Natal 59012-570, Brazil.ORCID 0000-0001-7623-4485
Universidade Federal do Rio Grande do Norte · BRUniversidad de Granada · ESUniversity of Perugia · IT

Funding

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior- Brazil (CAPES) 88887.131333/2016-00
6 · The paper itself

Abstract

This study aimed to develop a prolonged-release system based on palygorskite and chitosan, which are natural ingredients widely available, affordable, and accessible. The chosen model drug was ethambutol (ETB), a tuberculostatic drug with high aqueous solubility and hygroscopicity, which is incompatible with other drugs used in tuberculosis therapy. The composites loaded with ETB were obtained using different proportions of palygorskite and chitosan through the spray drying technique. The main physicochemical properties of the microparticles were determined using XRD, FTIR, thermal analysis, and SEM. Additionally, the release profile and biocompatibility of the microparticles were evaluated. As a result, the chitosan-palygorskite composites loaded with the model drug appeared as spherical microparticles. The drug underwent amorphization within the microparticles, with an encapsulation efficiency greater than 84%. Furthermore, the microparticles exhibited prolonged release, particularly after the addition of palygorskite. They demonstrated biocompatibility in an in vitro model, and their release profile was influenced by the proportion of inputs in the formulation. Therefore, incorporating ETB into this system offers improved stability for the administered product in the initial tuberculosis pharmacotherapy dose, minimizing its contact with other tuberculostatic agents in the treatment, as well as reducing its hygroscopicity.

Indexed as

chitosancompositedrug deliverypalygorskiteprolonged release

Identifiers

PMID37376170
PMCPMC10302483
OpenAlexW4380536505

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.